A Phase 2/3 interventional study of Cannabidiol, pharmaceutically produced with < 5 ppm THC and Placebo in COVID-19, Cardiovascular Diseases and Cardiovascular Risk Factor, sponsored by Cardiol Therapeutics Inc.. Terminated at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Cardiol Therapeutics Inc. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.
Among the 317 studies in COVID-19 with a site in Brazil, this one is the 184th largest by enrollment of the 263 interventional ones that give a count, is one of 103 that started in 2021, is one of 34 in phase 2/3, and was the 133rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Brazil, United States, Canada and 4 more countries
Ages 18–65
Pfizer · Sites in Brazil, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Brazil, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Brazil, United States, Argentina and 21 more countries
Ages 18+
Universidade Federal do Rio Grande do Norte · Sites in Brazil
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 104 · Phase 3 109 · Phase 4 14
First in 2015; this study’s year is marked. 103 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 205 across the 263 interventional studies, 598 across the 54 observational. Of the 215 that completed or were terminated, 82 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 317 have an industry lead sponsor. The 10 most frequent:
Cardiol Therapeutics Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Cardiol Therapeutics Inc. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in Brazil that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in COVID-19 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
Multi-center, double-blind, randomized, placebo-controlled, parallel group design. 1:1 randomization.
Screening (Day 0-1): Patients hospitalized for COVID-19 within the past 24 hours will be screened. If patient consent can be obtained, baseline assessments will be carried out: Physical examination (including vital signs), ECG including QTc interval assessment, echocardiogram to measure left-ventricular ejection fraction (LVEF), chest X-ray, local laboratory (including CBC, AST/ALT, alkaline phosphatase, bilirubin, creatinine/eGFR, INR, pregnancy test (in women with child-bearing potential only), lymphocyte count and LDH. A C-SSRS will also be completed. Frozen plasma will be retained for central analysis of CardiolRx™ levels, hs-troponin, NT-proBNP, D-dimer as well as inflammatory markers (hs-CRP, ferritin, TNF-alpha, IL-1 beta, IL-6, IL-10).
If all eligibility criteria are met, the patient will be randomized to either CardiolRx™ or placebo.
Study treatment will be initiated immediately after all baseline assessments have been completed and the patient is randomized (Day1). Oral administration is as follows:
If the next higher dose is not tolerated for other reasons, the dose will be reduced to the previous tolerated dose. The highest tolerated dose will be administered until Day 28.
If the patient is discharged before Day 10, the assessments up to Day 10 will be carried out as home visits. After Day 10, all remaining scheduled assessments will be carried out during out-patient visits (or home visits, if out-patient visits are not feasible).
In addition to prolongation of the QTc intervals, careful observation is required to detect other Adverse Drug Reactions (ADRs) and Drug-Drug Interactions (DDIs). Because CardiolRx™, may inhibit the metabolism of other drugs, new symptoms may represent toxicity from a concomitant medication that had previously been well tolerated.
A nasopharyngeal swab will also be done every day until Day 7 and on Day 14 to test for presence of the SARS-CoV-2 virus.
After Day 7, assessments will be carried out on a weekly basis except for as noted above on Day 10.
Frozen plasma will be retained for central analysis of CardiolRx™ levels, hs-troponin, NT-proBNP, D-dimer, inflammatory markers (hs-CRP, ferritin, TNF-alpha, IL-1 beta, IL-6, IL-10) and additional parameters of interest every two days until Day 7 as well as on day 28.
The assessments on Day 28 include the following: Physical examination (including vital signs), ECG (recorded 4 hours post morning dose for measurement of QTc interval), echocardiogram to measure LVEF, chest X-ray, local laboratory assessments, including CBC, AST/ALT, alkaline phosphatase, bilirubin, creatinine/eGFR, INR, lymphocyte count and LDH. In addition, a C-SSRS will be completed and the patient will be asked to answer a PICQ.
Further follow-up visits are scheduled for Day 45 and Day 60 post randomization. These include a clinical assessment (including vital signs) as well as the completion of the PICQ (PICQ on Day 60 only). Any changes in concomitant medications and (S)AEs will also be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Males and females 18 years of age or older 2. Hospitalized for COVID-19 with the most recent test positive*; not receiving or likely to receive invasive mechanical ventilation within the next 24 hours 3. Prior history of at least one of: i) CVD [cardiovascular (CV), cerebrovascular or peripheral vascular diagnoses], ii) Age > 64, iii) Diabetes (DM), iv) Hypertension (HTN), v) Abnormal serum lipids, vi) Obesity ( > or equal 30 or waist circumference >102 cm [40"] for men and >88 cm [35"] for women), vii) Current smoker
* Must be PCR test.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CardiolRx
Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC
Placebo
Drug: Placebo
Drug page: Cannabidiol
CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Also known as: CardiolRx
Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications
Proportions of patients in each group not having one of the outcome measures as described above (All-cause mortality, requirement for ICU admission and/or ventillatory support and cardiovascular complications)
Time frame: 28 days post randomization
Ordinal Outcome Scale
Ordinal Outcome Scale: 1. Not hospitalized and no limitations of activities. 2. Not hospitalized, with limitation of activities, home oxygen requirement, or both. 3. Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care. 4. Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care. 5. Hospitalized, requiring any supplemental oxygen. 6. Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices. 7. Hospitalized, receiving invasive mechanical ventilation or ECMO. 8. MI or stroke diagnosed since randomization. 9. Death.
Time frame: 28 days
| Milestone | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| Started | 45 | 45 |
| Completed | 41 | 37 |
| Not completed | 4 | 8 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Death | 0 | 2 |
Proportions of patients in each group not having one of the outcome measures as described above (All-cause mortality, requirement for ICU admission and/or ventillatory support and cardiovascular complications)
| Participants | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications | 3 | 2 |
Ordinal Outcome Scale: 1. Not hospitalized and no limitations of activities. 2. Not hospitalized, with limitation of activities, home oxygen requirement, or both. 3. Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care. 4. Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care. 5. Hospitalized, requiring any supplemental oxygen. 6. Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices. 7. Hospitalized, receiving invasive mechanical ventilation or ECMO. 8. MI or stroke diagnosed since randomization. 9. Death.
| score on a scale | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| Ordinal Outcome Scale | 1.40 ± 1.39 | 1.51 ± 1.85 |
Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | 0/45 (0%) | 5/45 (11.1%) | 24/45 (53.3%) |
| Placebo | 2/44 (4.5%) | 4/44 (9.1%) | 23/44 (52.3%) |
| Event | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| TachycardiaCardiac disorders | 0/45 | 1/44 |
| Septic ShockInfections and infestations | 0/45 | 1/44 |
| ALT increaseInvestigations | 0/45 | 1/44 |
| Acute kidney injuryRenal and urinary disorders | 0/45 | 1/44 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/45 | 1/44 |
| Cardiac failureCardiac disorders | 1/45 | 0/44 |
| PneumoniaInfections and infestations | 1/45 | 0/44 |
| QTC segment prolongationInvestigations | 1/45 | 0/44 |
| Renal impairmentRenal and urinary disorders | 1/45 | 0/44 |
| Event | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 5/45 | 2/44 |
| HeadacheNervous system disorders | 4/45 | 3/44 |
| ConstipationGastrointestinal disorders | 2/45 | 3/44 |
| DyspepsiaGastrointestinal disorders | 2/45 | 3/44 |
| DizzinessNervous system disorders | 0/45 | 3/44 |
| TachycardiaCardiac disorders | 0/45 | 3/44 |
| DysgeusiaNervous system disorders | 3/45 | 2/44 |
| HypertensionVascular disorders | 3/45 | 1/44 |
| SomnolenceNervous system disorders | 1/45 | 2/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/45 | 2/44 |
| Age, Continuous(years) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Mean | 60.4 ± 14.86 | 62.0 ± 12.95 | 61.2 ± 13.89 |
| Sex: Female, Male(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Female | 19 | 20 | 39 |
| Male | 26 | 25 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 42 | 42 | 84 |
| Not Hispanic or Latino | 3 | 3 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 28 | 27 | 55 |
| More than one race | 15 | 15 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| United States | 25 | 26 | 51 |
| Brazil | 6 | 4 | 10 |
| Mexico | 14 | 15 | 29 |
| Obesity(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Count of participants | 19 | 23 | 42 |
| Diabetes(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Count of participants | 17 | 19 | 36 |
| Hyperlipidemia(Participants) | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo | Total |
|---|---|---|---|
| Count of participants | 7 | 9 | 16 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data will become available once the study has been published
Supporting information: Study protocol
Time frame: Data will become available in Q4 2022
Access criteria: Access to the journal in which article has been published
Ran from Apr 2021 to primary completion in Nov 2022, 19 months.
Results were first posted in Jul 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Cardiol Therapeutics Inc.